Protocols

AdoRx raises $10M for adenosine program in cancer; Molecular Partners poaches Regeneron, recruiting Pamela Trail as CSO

→ A day after iTeos raised $75 million to accelerate its research plans on an adenosine program for cancer, a new rival has sprung up in Scotland. AdoRx has raised $10 million from Epidarex Capital and CRT Pioneer Fund, after getting some seed cash together for a launch last year. CEO Peter Finan is a partner at Epidarex and has senior-level experience handling research at the Novartis Institutes for BioMedical Research. 

Molecular Partners has raided Regeneron’s oncology team for its new CSO. Pamela Trail, who served most recently as Vice President of Oncology Strategy and Program Direction at Regeneron, is taking the job. Current CSO Michael T. Stumpp, meanwhile, is moving over to the COO position. 


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->